© 2000 by European Society of Cardiology
REVIEW
Arrhythmogenic mechanisms in left ventricular hypertrophy
Department of Cardiology, Medical Centre for Postgraduate Education Warsaw, Poland
An important mechanism contributing to the high mortality and sudden death in patients with left ventricular hypertrophy (LVH) is ventricular arrhythmia. Part of the risk is associated with the pro-arrhythmic electrophysiological phenotype of the hypertrophied myocardium. The most consistently observed abnormality is prolongation of the action potential duration and refractoriness, which sets the stage for arrhythmias based on early or delayed afterdepolarizations and triggered activity. In addition, non-uniform prolongation of the action potential in LVH may be pro-arrhythmic by leading to increased dispersion of repolarization or refractoriness and favouring re-entry. The occurrence of delayed afterdepolarization-induced triggered activity and other ventricular arrhythmias are also related to the impaired ability to handle intracellular calcium due to changes in the density of ryanodine receptors and the Ca2+-ATPase of the sarcoplasmic reticulum. Slowing and fractionation of ventricular conduction, creating the conditions for micro-reentry and arrhythmogenesis, are characteristic of severe LVH, as isthe expression of the Ifcurrent (which may be a source of increased automaticity).
The pro-arrhythmic potential of LVH is also related to the presence of coexisting ‘extrinsic’ factors. The most important and pro-arrhythmic association of LVH is that with myocardial ischaemia. Other conditions include neuroendocrine factors, ventricular wall stress or electrolyte disturbances. The electrophysiological mechanisms of the interactions between these ‘extrinsic’ factors and LVH have not been fully elucidated. Further research into these mechanisms is required and may have important implications for our understanding of the mechanisms of cardiac arrhythmias in LVH and the appropriate use of antiarrhythmic drug therapy.
Key Words: Sudden death, hypertrophy, arrhythmias, ischaemia
Correspondence: Dr Robert Wolk, Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Grenadierow 51/59, 04-073 Warsaw, Poland.
[1] Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75:Suppl. 3A 4–11.
[2] Wolk R and Cobbe SM. Cardiac arrhythmias in hypertrophy. In Sheridan DJ (Ed.). Left Ventricular Hypertrophy 1998; London Churchill Livingstone pp. 101–106.
[3] Ghali JK, Kadakia S, Cooper RS, Liso Y. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277–1282.
[4] Schmieder RE and Messerli FH. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 1992; 123: 89–95.
[5] Vester EG, Kuhls S, Ochiulet-Vester J, Vogt M, Strauer BE. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992; 13:Suppl. D 70–81.
[6] Lavie CJ Jr, Nunez BD, Garavaglia GE, Messerli FH. Hypertensive concentric left ventricular hypertrophy: when is ventricular ectopic activity increased? South Med J 1988; 81: 696–700.
[7] James MA and Jones JV. Ventricular arrhythmia in untreated newly presenting hypertensive patients compared with a matched normal population. J Hypertens 1989; 7: 409–415.
[8] Manyari DE, Patterson C, Johnson D, Melendez L, Kostuk WJ, Cape RD. Atrial and ventricular arrhythmias in asymptomatic active elderly subjects: correlation with left atrial size and left ventricular mass. Am Heart J 1990; 119: 1069–1076.
[9] Kowey P, Friehling TD, Sewter J, et al. Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation 1991; 83: 2067–2075.
[10] Kowey PR, O'Brien R, Wu Y, et al. Effect of gallopamil on electrophysiologic abnormalities and ventricular hypertrophy in the feline heart. Am Heart J 1992; 124: 898–905.
[11] Rials SJ, Wu Y, Ford N, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 1995; 91: 426–430.
[12] Gillis AM, Mathison HJ, Kulisz E, Lester WM. Dispersion of ventricular repolarization and ventricular fibrillation in left ventricular hypertrophy: influence of selective potassium channel blockers. J Pharmacol Exp Ther 2000; 292: 381–386.
[13] Messerli FH, Nuñez BD, Nuñez MM, Garavaglia GE, Schmieder RE, Ventura HO. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989; 149: 1263–1267.
[14] Malerba M, Muiesan ML, Zulli R, Rizzoni D, Calebich S, Agabiti Rosei E. Ventricular arrhythmias and changes in blood pressure and left ventricular mass induced by antihypertensive treatment in hypertensive patients. J Hypertens 1991; 9:Suppl. 6 S162–164.
[15] González-Fernández RA, Rivera M, Rodríguez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens 1993; 6: 308–313.
[16] Kohya T, Yokoshiki H, Tohse N, et al. Regression of left ventricular hypertrophy prevents ischaemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892–899.
[17] Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rat. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996; 28: 269–275.
[18] Yokoshiki H, Kohya T, Tomita F, et al. Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Moll Cell Cardiol 1997; 29: 1331–1339.
[19] Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–352.
[20] Devereaux R, Roman M, Ganau A, de Simone G, Okin P, Kligfield P. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension 1994; 23: 802–809.
[21] Levy D, Anderson KM, Plehn J, Savage DD, Christiansen JC, Castelli WP. Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol 1987; 59: 836–840.
[22] Nunez BD, Lavie CJ, Messerli FH, Schmieder RE, Garavaglia GE, Nunez M. Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 1994; 74: 585–589.
[23] Bethge C, Motz W, Hehn AV, Strauer BE. Ventricular arrhythmia in hypertensive heart disease with and without heart failure. J Cardiovasc Pharmacol 1987; 10:Suppl_6 S119–128.
[24] Pye MP and Cobbe SM. Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc Res 1992; 26: 740–750.
[25] Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994; 28: 933–946.
[26] Boyden PA and Jeck CD. Ion channel function in disease. Cardiovasc Res 1995; 29: 312–318.
[27] Antzelevitch C and Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarisations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23: 259–277.
[28] Aronson RS. Afterpotentials and triggered activity in hypertrophied myocardium from rats with renal hypertension. Circ Res 1981; 48: 720–727.
[29] Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992; 20: 1576–1584.
[30] Charpentier F, Baudet S, Le Marec H. Triggered activity as a possible mechanism for arrhythmias in ventricular hypertrophy. PACE 1991; 14: 1735–1741.
[31] Bryant SM, Shipsey SJ, Hart G. Regional differences in electrical and mechanical properties of myocytes from guinea-pig hearts with mild left ventricular hypertrophy. Cardiovasc Res 1997; 35: 315–323.
[32] Shipsey SJ, Bryant SM, Hart G. Effects of hypertrophy on regional action potential characteristics in the rat left ventricle. A cellular basis for T-wave inversion. Circulation 1997; 96: 2061–2068.
[33] McIntosh MA, Cobbe SM, Kane KA, Rankin AC. Action potential prolongation and potassium currents in left ventricular myocytes isolated from hypertrophied rabbit hearts. J Mol Cell Cardiol 1998; 30: 43–53.
[34] Wolk R, Sneddon KP, Kane KA, Cobbe SM, Hicks MN. Regional electrophysiological effects of left ventricular hypertrophy in isolated whole hearts under normal and ischaemic conditions, Cardiovasc Res. In revision.
[35] Cameron JS, Miller LS, Kimura S, et al. Systemic hypertension induces disparate localized left ventricular action potential lengthening and altered sensitivity to verapamil in left ventricular myocardium. J Mol Cell Cardiol 1986; 18: 169–175.
[36] Carré F, Rannou F, Sainte Beuve C, et al. Arrhythmogenicity of the hypertrophied and senescent heart in relationship to membrane proteins involved in the altered calcium handling. Cardiovasc Res 1993; 27: 1784–1789.
[37] Gwathmey JK and Morgan JP. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 1985; 57: 836–843.
[38] Merillat JC, Lakatta EG, Hano O, Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 1990; 67: 1115–1123.
[39] Perreault CL, Williams CP, Morgan JP. Cytoplasmic calcium modulation and systolic versus diastolic dysfunction in myocardial hypertrophy and failure. Circulation 1993; 87:Suppl. VII 31–37.
[40] Swynghedauw B, Chevalier B, Charlemagne D, Mansier P, Carré F. Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Cardiovasc Res 1997; 35: 6–12.
[41] Hittinger L, Ghaleh B, Edwards JG, et al. Reduced subendocardial ryanodine receptors and consequent effects on cardiac function in conscious dogs with left ventricular hypertrophy. Circ Res 1999; 84: 999–1006.
[42] Winterton SJ, Turner MA, O'Gorman DJ, Flores NA, Sheridan DJ. Hypertrophy causes delayed conduction in human and guinea pig myocardium: accentuation during ischaemic perfusion. Cardiovasc Res 1994; 28: 47–54.
[43] Cooklin M, Wallis WRJ, Sheridan DJ, Fry CH. Changes in cell-to-cell electrical coupling associated with left ventricular hypertrophy. Circ Res 1997; 80: 765–771.
[44] Peters NS, Del Monte F, Macleod KT, Green CR, Poole-Wilson PA, Severs NJ. Increased cardiac myocyte gap-junctional membrane early in renovascular hypertension (Abstr). J Am Coll Cardiol 1993; 21: 59A.
[45] Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischaemic human hearts. Circulation 1993; 88: 864–875.
[46] Bastide B, Neyses L, Ganten D, Paul M, Willecke K, Traub O. Gap junction protein connexin40 is preferentially expressed in vascular endothelium and conductive bundles of rat myocardium and is increased under hypertensive conditions. Circ Res 1993; 73: 1138–1149.
[47] Sepp R, Severs NJ, Gourdie RG. Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart 1996; 76: 412–417.
[48] Janse MJ. Reentrant arrhythmias. In Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (Eds.). The Heart and the Cardiovascular System 1992; 2nd edn New York Raven Press pp. 2055–2094.
[49] Weber KT, Janicki JS, Pick R, et al. Collagen in the hypertrophied, pressure-overloaded myocardium. Circulation 1987; 75:Suppl. I I-40–I-47.
[50] Weber KT and Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–1865.
[51] Assayag P, Carré F, Chevalier B, Delcayre C, Mansier P, Swynghedauw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res 1997; 34: 439–444.
[52] Spach MS and Josephson ME. Initiating reentry: the role of non-uniform anisotropy in small circuits. J Cardiovasc Electrophysiol 1994; 5: 182–209.
[53] Cerbai E, Barbieri M, Mugelli A. Characterization of the hyperpolarization-activated current, If, in ventricular myocytes isolated from hypertensive rats. J Physiol 1994; 481: 585–591.
[54] Cerbai E, Barbieri M, Mugelli A. Occurrence and properties of the hyperpolarization-activated current Ifin ventricular myocytes from normotensive and hypertensive rats during aging. Circulation 1996; 94: 1674–1681.
[55] Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med 1989; 110: 101–107.
[56] Weber K, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23: 869–877.
[57] Scheler S, Motz W, Stauer B. Mechanism of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. Am J Cardiol 1994; 73: 478–482.
[58] Wallbridge DR and Cobbe SM. Coronary haemodynamics in left ventricular hypertrophy. Heart 1996; 75: 369–376.
[59] Koyanagi S, Eastham C, Marcus ML. Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs. Circulation 1982; 65: 1192–1197.
[60] Bélichard P, Pruneau D, Rochette L. Influence of spontaneous hypertension and cardiac hypertrophy on the severity of ischemic arrhythmias in the rat. Basic Res Cardiol 1988; 83: 560–566.
[61] Kohya T, Kimura S, Myerburg RJ, Bassett AL. Susceptibility of hypertrophied rat hearts to ventricular fibrillation during acute ischaemia. J Mol Cell Cardiol 1988; 20: 159–168.
[62] Martins JB, Kim W, Marcus ML. Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs 3 hours after left circumflex coronary occlusion. J Am Coll Cardiol 1989; 14: 1365–1373.
[63] Janse MJ and Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischaemia and infarction. Physiol Rev 1989; 69: 1049–1169.
[64] Bélichard P, Pruneau D, Rouet R, Salzmann JL. Electrophysiological responses of hypertrophied rat myocardium to combined hypoxia, hyperkalemia, and acidosis. J Cardiovasc Pharmacol 1991; 17:Suppl 2 S141–145.
[65] Hicks MN, McIntosh MA, Kane KA, Rankin AC, Cobbe SM. The electrophysiology of rabbit hearts with left ventricular hypertrophy under normal and ischaemic conditions. Cardiovasc Res 1995; 30: 181–186.
[66] Cameron JS, Kimura S, Jackson-Burns DA, Smith DB, Bassett AL. ATP-sensitive K+channels are altered in hypertrophied ventricular myocytes. Am J Physiol 1988; 255: H1254–1258.
[67] Kimura S, Bassett AL, Xi H, Tomita F, Myerburg RJ. Characteristics of ATP-sensitive K+channels in hypertrophied cells: effect of pH (Abstr). Circulation 1992; 86:Suppl. I I-92.
[68] Furukawa T, Myerburg RJ, Furukawa N, Kimura S, Bassett AL. Metabolic inhibition of ICa,Land IKdiffers in feline left ventricular hypertrophy. Am J Physiol 1994; 266: H1121–1131.
[69] Yuan F, Brandt NR, Pinto JMB, Wasserlauf BJ, Myerburg RJ, Bassett AL. Hypertrophy decreases cardiac KATPchannel responsiveness to exogenous and locally generated (glycolytic) ATP. J Mol Cell Cardiol 1997; 29: 2837–2848.
[70] Lee SW, Schwartz A, Adams RJ, et al. Decrease in Na+,K+-ATPase activity and [3H]Ouabain binding sites in sarcolemma prepared from hearts of spontaneously hypertensive rats. Hypertension 1983; 5: 682–688.
[71] Vermeulen JT, Tan HL, Rademaker H, et al. Electrophysiologic and extracellular ionic changes during acute ischemia in failing and normal rabbit myocardium. J Mol Cell Cardiol 1996; 28: 123–131.
[72] Oldershaw PJ and Cameron IRC. The effects of long-standing hypertensive left ventricular hypertrophy on intracellular pH and intracellular electrolytes in rats. Int J Cardiol 1988; 18: 143–149.
[73] Wallis WRJ, Wu C, Sheridan DJ, Fry CH. Intracellular pH and H+buffering capacity in guinea-pig left ventricular hypertrophy induced by constriction of the thoracic aorta. Exp Physiol 1997; 82: 227–230.
[74] Schömig A. Catecholamines in myocardial ischaemia. Systemic and cardiac release. Circulation 1990; 82:Suppl. II II-13–II-22.
[75] Schömig A, Haass M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 1991; 12:Suppl F 38–47.
[76] Strasser RH, Marquetant R, Kübler W. Adrenergic receptors and sensitization of adenylyl cyclase in acute myocardial ischemia. Circulation 1990; 82:Suppl. II II-23–II-29.
[77] Thandroyen FT, Muntz KH, Buja LM, Willerson JT. Alterations in ß-adrenergic receptors, adenylate cyclase, and cyclic AMP concentrations during acute myocardial ischemia and reperfusion. Circulation 1990; 82:Suppl. II II-30–II-37.
[78] Strasser RH and Marquetant R. Sensitization of the ß-adrenergic system in acute myocardial ischaemia by a protein kinase C-dependent mechanism. Eur Heart J 1991; 12:Suppl F 48–53.
[79] Postnov YV. An approach to the explanation of cell membrane alteration in primary hypertension. Hypertension 1990; 15: 332–337.
[80] Livne AA, Aharonovitz O, Paran E. Higher Na+/H+exchange rate and more alkaline intracellular pH set-point in essential hypertension: effects of protein kinase modulation in platelets. J Hypertens 1991; 9: 1013–1019.
[81] Pérez NG, Alvarez BV, Camilión de Hurtado MC, Cingolani HE. pHiRegulation in myocardium of the spontaneously hypertensive rat. Compensated enhanced activity of the Na+/H+exchanger. Circ Res 1995; 77: 1192–1200.
[82] Schussheim AE and Radda GK. Altered Na+/H+exchange activity in the spontaneously hypertensive perfused rat heart. J Mol Cell Cardiol 1995; 27: 1475–1481.
[83] Wolk R, Cobbe SM, Hicks MN, Kane KA. Functional, structural and dynamic bases of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and antiarrhythmic drug therapy. Pharmacology & Therapeutics 1999; 84: 207–231.
[84] Schwarz PJ and Priori SG. Sympathetic nervous system and cardiac arrhythmias. In Zipes DP and Jalife J (Eds.). Cardiac Electrophysiology. From Cell to Bedside 1990; Philadelphia WB Saunders Co pp. 330–343.
[85] Barron HV and Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996; 27: 1053–1060.
[86] Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1989; 14: 177–183.
[87] Brush JE Jr, Eisenhofer G, Garty M, et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 1989; 79: 836–844.
[88] Kelm M, Schäfer S, Mingers S, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14: 1357–1364.
[89] Agabiti-Rosei G, Malerba M, Rizzoni D, et al. Ventricular arrhythmias as related to adrenergic activity in untreated patients with cardiac hypertrophy (Abstr). Am J Hypertens 1990; 3:Part 2 2A.
[90] Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol 1993; 4: 338–555.
[91] Schillaci G, Verdecchia P, Borgioni C, et al. Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. Hypertension 1996; 28: 284–289.
[92] Martinez ML, Fernandez-Tome P, Lopez-Miranda V, Colado MI, Delgado C. Modulation of adrenergic receptors during left ventricular hypertrophy development and after regression by captopril. J Cardiovasc Pharmacol 1999; 34: 505–511.
[93] Scholz PM, Upsher ME, Eliades D, Kedem J, Weiss HR. Alterations in the regional beta adrenergic system in experimental left ventricular hypertrophy. Cardiovasc Res 1990; 24: 65–71.
[94] Ganguly PK, Lee SL, Beamish RE, Dhalla NS. Altered sympathetic system and adrenoceptors during the development of cardiac hypertrophy. Am Heart J 1989; 118: 520–525.
[95] Galinier M, Senard JM, Valet P, et al. Cardiac beta-adrenoceptors and adenylyl cyclase activity in human left ventricular hypertrophy due to pressure overload. Fundam Clin Pharmacol 1994; 8: 90–99.
[96] Ayobe MH and Tarazi RC. Beta-receptors and contractile reserve in left ventricular hypertrophy. Hypertension 1983; 5: 1192–1197.
[97] Bohm M, Beuckelmann D, Diet F, Feiler G, Lohse MJ, Erdmann E. Properties of cardiac alpha- and beta-adrenoceptors in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 1988; 338: 383–391.
[98] Bohm M, Beuckelmann D, Brown L, et al. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 1988; 9: 844–852.
[99] Franz MR. Stretch-activated arrhythmias. In Zipes DP and Jalife J (Eds.). Cardiac Electrophysiology. From Cell to Bedside 1994; 2nd edn Philadelphia W.B. Saunders Co pp. 597–606.
[100] Sideris DA, Kontoyannis DA, Michalis L, Adractas A, Moulopoulos SD. Acute changes in blood pressure as a cause of cardiac arrhythmias. Eur Heart J 1987; 8: 45–52.
[101] Taggart P, Sutton P, Lab MJ, Runnals M, Obrian W, Treasure T. Effect of abrupt changes in ventricular loading on repolarization induced by transient aortic occlusion in humans. Am J Physiol 1992; 263: H816–823.
[102] James MA and Jones JV. The paradoxical role of left ventricular hypertrophy in wall stress-related arrhythmia. J Hypertens 1992; 10: 167–172.
[103] Jauch W, Hicks MN, Cobbe SM. Effects of contraction-excitation feedback on electrophysiology and arrhythmogenesis in rabbits with experimental left ventricular hypertrophy. Cardiovasc Res 1994; 28: 1390–1396.
[104] Evans SJ, Levi AJ, Jones JV. Wall stress induced arrhythmia is enhanced by low potassium and early ventricular hypertrophy in the working rat heart. Cardiovasc Res 1995; 29: 555–562.
[105] Evans SJ, Levi AJ, Jones JV. Low magnesium enhances the pro-arrhythmic effect of low potassium in the hypertrophied rat heart but not in the normal rat heart. J Hypertens 1996; 14: 635–644.
[106] Helfant RH. Hypokalemia and arrhythmias. Am J Med 1986; 80:Suppl 4A 13–22.
[107] Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 1992; 85:Suppl I I-70–I-76.
[108] Caralis PV, Materson BJ, Perez-Stable E. Potassium and diuretic induced ventricular arrhythmias in ambulatory hypertensive patients. Miner Electrolyte Metab 1984; 10: 148–154.
[109] Hollifield JW. Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med 1986; 80:Suppl 4A 8–12.
[110] Cohen JD, Neaton JD, Prineas RJ, et al. Diuretics, serum potassium and ventricular arrhythmias in the multiple risk factor intervention trial. Am J Cardiol 1987; 60: 548–554.
[111] Ryan MP. The effects of diuretics on magnesium and potassium homeostasis. In Itokawa Y and Durlach J (Eds.). Magnesium in Health and Disease 1989; Paris John Libbey and Co. Ltd pp. 397–408.
[112] James MA and Jones JV. Ventricular arrhythmia in untreated newly presenting hypertensive patients compared with a matched normal population. J Hypertens 1989; 7: 409–415.
[113] Multiple Risk Factor Intervention Trial research group. Multiple Risk Factor Intervention Trial. JAMA 1982; 248: 1465–1477.
[114] Holme I, Helgland A, Hjermann I, Leren P, Lund-Larsen P. Treatment of mild hypertension with diuretics. JAMA 1984; 251: 1298–1299.
[115] MRC. Trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97–104.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Wolk Calcineurin, myocardial hypertrophy, and electrical remodeling Cardiovasc Res, February 1, 2003; 57(2): 289 - 293. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||